The MetroHealth System completes vector and cellular facility

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MetroHealth completed its vector and cellular Good Manufacturing Practice facility that will enable quick, reliable production and processing of the latest cellular immunotherapies, including CAR T-cell and tumor-infiltrating lymphocytes cancer therapies. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab), in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) followed by Sarclisa-Rd (the IMROZ regimen), significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly-diagnosed multiple myeloma not eligible for transplant. 

Login